Description: InnoCan Pharma Corporation focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in Israel. It engages in the research and development of Covid-19 treatment and other viruses causing lung inflammation, as well as other central nervous system diseases, such as epilepsy and Alzheimer's disease; and CBD loaded liposomes that provides pain relief, and treat epilepsy, other central nervous system disorders, and other indications. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. In addition, it develops SHIR premium CBD facial serum products. The company was incorporated in 2018 and is headquartered in Calgary, Canada.
Home Page: innocanpharma.com
1015, 926 – 5 Avenue SW
Calgary,
AB
T2P 0N7
Canada
Phone:
403-777-1519
Officers
| Name | Title |
|---|---|
| Mr. Ron Mayron | Executive Chairman |
| Ms. Iris Bincovich | CEO & Director |
| Mr. Nelson Harvey Halpern F.C.A., FCPA | Chief Financial Officer |
| Mr. Roni Kamhi | COO & CEO of BI Sky Global and Director |
| Mr. Eyal Flom L.L.M., M.B.A. | Director & Company Secretary |
| Mr. Yoram Drucker | Founder & Executive VP of Business Development |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.7329 |
| Price-to-Sales TTM: | 1.4908 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |